Carolina Urologic Research Center

Summary

Carolina Urologic Research Center is a medical facility located in Myrtle Beach, South Carolina. This center is recognized for care of Prostate Cancer, Bladder Cancer, Transitional Cell Carcinoma, Cancer, Enlarged Prostate and other specialties. Carolina Urologic Research Center is involved with conducting 158 clinical trials across 103 conditions. There are 3 research doctors associated with this hospital, such as Neal Shore, Abhishek Srivastava, MD, and Robert Jansen, MD.

Top PIs

Clinical Trials running at Carolina Urologic Research Center

Prostate Cancer

Bladder Cancer

Kidney Cancer

Lung Cancer

Ovarian Cancer

Cervical Adenocarcinoma

Kennedy's Disease

Relapse

Transitional Cell Carcinoma

Squamous Cell Carcinoma

Lutetium (177Lu) Vipivotide Tetraxetan

for Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).

Recruiting

2 awards

Phase 3

6 criteria

64Cu-SAR-bisPSMA PET Scan

for Prostate Cancer

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Recruiting

2 awards

Phase 3

5 criteria

AAA817 + ARPI

for Prostate Cancer

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

Recruiting

2 awards

Phase 3

7 criteria